Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Sterilization Methods Receive Guidelines For 510(k) Submissions

Executive Summary

New guidance from the FDA clarifies premarket submission details for devices sterilized with novel methods.

You may also be interested in...



The FDA Unleashes The Beast: A New Tiger Team For Sterilization

The second meeting in a series of town halls by the FDA announced the creation of a Tiger Team dedicated to medical device sterilization innovation.

Vaporized Hydrogen Peroxide Moved To Established Category A, And Other Updates From FDA’s EtO Town Hall

A US FDA town hall explained the vaporized hydrogen peroxide category update and set the stage for a series of meetings to come.

Harmonizing EPA And Industry Needs: EtO Emissions

The EPA and medtech industry want the same things: Cleaner air and a steady supply of medical devices. So how do they reconcile their differences?

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel